This is an open, multicenter Phase I/II clinical trial of LBL-033 in the treatment of patients with advanced malignant tumors，which aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, and effectiveness.~The trial is divided into 2 parts: Phase 1 and Phase 2~Phase I study:~Dose-escalation and PK expansion.The PK expansion study will be judged on the basis of dose escalation data.~Phase II study:~Dose expansion included 4 cohorts that required patients with MUC16-positive malignancies.Blood samples will be collected from all subjects in this trial.~Phase I and Phase II studies are expected to recruit 113-468 patients
This trial is an open and multicenter phase I/II clinical study, which aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, and effectiveness.